IKT Stock Summary and Trading Ideas (Inhibikase Therapeutics | NASDAQ:IKT)

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Inhibikase Therapeutics trades on the NASDAQ stock market under the symbol IKT.

As of September 14, 2026, IKT stock price climbed to $2.39 with 447,831 million shares trading.

IKT has a beta of 0.95, meaning it tends to be less sensitive to market movements. IKT has a correlation of 0.05 to the broad based SPY ETF.

IKT has a market cap of $333.49 million. This is considered a Small Cap stock.

In the last 3 years, IKT traded as high as $4.20 and as low as $.79.

The top ETF exchange traded funds that IKT belongs to (by Net Assets): VTI, IWM, IWN, VXF, VTWO.

IKT has outperformed the market in the last year with a price return of +42.3% while the SPY ETF gained +16.8%. IKT has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +43.1% and -0.8%, respectively, while the SPY returned +3.4% and -1.1%, respectively.

IKT support price is $2.26 and resistance is $2.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IKT shares will trade within this expected range on the day.